Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Relmada Therapeutics Inc.

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Relmada Therapeutics Provides Corporate Update
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.